NASDAQ:DRTS Alpha Tau Medical (DRTS) Stock Price, News & Analysis $2.48 -0.10 (-3.72%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Alpha Tau Medical Stock (NASDAQ:DRTS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Alpha Tau Medical alerts:Sign Up Key Stats Today's Range$2.45▼$2.6050-Day Range$2.50▼$4.2052-Week Range$1.75▼$4.39Volume21,497 shsAverage Volume48,713 shsMarket Capitalization$174.54 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingBuy Company OverviewAlpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Read More… Remove Ads Alpha Tau Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreDRTS MarketRank™: Alpha Tau Medical scored higher than 40% of companies evaluated by MarketBeat, and ranked 668th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAlpha Tau Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAlpha Tau Medical has only been the subject of 1 research reports in the past 90 days.Read more about Alpha Tau Medical's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Alpha Tau Medical are expected to decrease in the coming year, from ($0.45) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alpha Tau Medical is -5.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alpha Tau Medical is -5.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlpha Tau Medical has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.23% of the float of Alpha Tau Medical has been sold short.Short Interest Ratio / Days to CoverAlpha Tau Medical has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alpha Tau Medical has recently increased by 60.74%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlpha Tau Medical does not currently pay a dividend.Dividend GrowthAlpha Tau Medical does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.23% of the float of Alpha Tau Medical has been sold short.Short Interest Ratio / Days to CoverAlpha Tau Medical has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alpha Tau Medical has recently increased by 60.74%, indicating that investor sentiment is decreasing significantly. News and Social Media1.8 / 5News Sentiment0.24 News SentimentAlpha Tau Medical has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Alpha Tau Medical this week, compared to 1 article on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Alpha Tau Medical insiders have not sold or bought any company stock.Percentage Held by Insiders39.50% of the stock of Alpha Tau Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.65% of the stock of Alpha Tau Medical is held by institutions.Read more about Alpha Tau Medical's insider trading history. Receive DRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alpha Tau Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address DRTS Stock News HeadlinesAlpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent GlioblastomaApril 2 at 8:30 AM | globenewswire.comHead-To-Head Survey: Vivos Therapeutics (NASDAQ:VVOS) versus Alpha Tau Medical (NASDAQ:DRTS)March 28, 2025 | americanbankingnews.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 3, 2025 | Porter & Company (Ad)Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate UpdateMarch 12, 2025 | globenewswire.comAlpha Tau to Participate in March Investor ConferencesFebruary 27, 2025 | markets.businessinsider.comAlpha Tau Receives Medical Device Single Audit Program (MDSAP) CertificationFebruary 24, 2025 | globenewswire.comAlpha Tau announces FDA approval of IDE supplementFebruary 3, 2025 | msn.comAlpha Tau DaRT Shows Promising Interim Data In Cancer Trials, Shares RiseJanuary 29, 2025 | nasdaq.comSee More Headlines DRTS Stock Analysis - Frequently Asked Questions How have DRTS shares performed this year? Alpha Tau Medical's stock was trading at $3.10 at the start of the year. Since then, DRTS stock has decreased by 20.0% and is now trading at $2.48. View the best growth stocks for 2025 here. How were Alpha Tau Medical's earnings last quarter? Alpha Tau Medical Ltd. (NASDAQ:DRTS) announced its earnings results on Wednesday, March, 12th. The company reported ($0.13) earnings per share for the quarter, meeting the consensus estimate of ($0.13). How do I buy shares of Alpha Tau Medical? Shares of DRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alpha Tau Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alpha Tau Medical investors own include Datadog (DDOG), Advanced Micro Devices (AMD), Broadcom (AVGO), Meta Platforms (META), PayPal (PYPL), Sunrun (RUN) and ZIM Integrated Shipping Services (ZIM). Company Calendar Last Earnings3/12/2025Today4/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:DRTS CIK1871321 Webhealthcarecapitalcorp.com Phone972-3577-4115FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$9.00 Low Stock Price Target$7.00 Potential Upside/Downside+210.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.62% Return on Assets-29.89% Debt Debt-to-Equity Ratio0.08 Current Ratio10.99 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.21 per share Price / Book2.13Miscellaneous Outstanding Shares70,381,000Free Float42,304,000Market Cap$181.58 million OptionableNo Data Beta0.87 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:DRTS) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alpha Tau Medical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alpha Tau Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.